GlaxoSmithKline Consumer Healthcare Pakistan : Approval of Company Name Change - Haleon Pakistan Limited
January 06, 2023 at 06:42 am EST
Share
6 January 2023
The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building,
Stock Exchange Road,
Karachi.
Subject:
Disclosure of Material Information - Approval of Name Change
Dear Sir / Madam,
This is with reference to section 96 of the Securities Act, 2015 and Clause 5.6.1(a) of PSX Limited Regulations. The Company hereby conveys the following material information:
The name of the Company has been changed to Haleon Pakistan Limited and a Certificate of Incorporation on Change of Name has been issued by the Securities and Exchange Commission of Pakistan in this respect dated 3 January 2023.
The name "Haleon Pakistan Limited" shall be accompanied by the phrase "Formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited" in parenthesis as prescribed under section 13 of the Companies Act, 2017.
This shall have no effect on the principal line of business of the Company. The disclosure form in terms of Section 96 of the Securities Act, 2015 is also attached.
You may please inform the TRE Certificate holders of the Exchange accordingly
Yours truly,
For and on Behalf of Haleon Pakistan Limited (formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited)
Ms. Mashal Mohammad
Company Secretary
Executive Director / HOD,
Offsite-II Department, Supervision Division, Securities and Exchange Commission of Pakistan,
63, NIC Building, Jinnah Avenue, Blue Area, Islamabad.
Continued
Page 2 of 2
SCHEDULE
DISCLOSURE FORM
Name of Company:
Haleon Pakistan Limited (formerly known as GlaxoSmithKline Consumer
Healthcare Pakistan Limited)
Registered Office
Sandoz Nagar, Petaro Road, Jamshoro Sindh, 76100.
Date of Report:
6 January 2023
Contact Information:
Mashal Mohammad
Company Secretary
Telephone No.:
+92-111-475-725
Fax No.:
N/A
Email Address:
pakistan.shareinfo@haleon.com
Disclosure of price sensitive information by listed company in terms of Section 96 of the Securities Act 2015.
The name of the Company has been changed to Haleon Pakistan Limited and a Certificate of Incorporation on Change of Name has been issued by the Securities and Exchange Commission of Pakistan in this respect dated 3 January 2023.
The name "Haleon Pakistan Limited" shall be accompanied by the phrase "Formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited" in parenthesis as prescribed under section 13 of the Companies Act, 2017.
This shall have no effect on the principal line of business of the Company.
For and on Behalf of Haleon Pakistan Limited (formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited)
Ms. Mashal Mohammad
Company Secretary
Attachments
Original Link
Original Document
Permalink
Disclaimer
Glaxosmithkline Consumer Healthcare Pakistan Ltd. published this content on 06 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 January 2023 11:25:09 UTC.
Haleon Pakistan Limited, formerly Glaxosmithkline Consumer Healthcare Pakistan Limited, is a Pakistan-based healthcare company. The Company's product portfolio consists of five categories, namely oral health, pain relief, respiratory health, digestive health and other, and vitamins, minerals and supplements (VMS). Its geographical segment consists of North America; Europe, Middle East & Africa (EMEA) and Latin America (LatAm), and Asia-Pacific (APAC). The Brands under Oral Health include Sensodyne, Parodontax, Polident, and Biotene. Its Vitamins, Minerals and Supplements offers a portfolio of brands, such as Centrum, a multivitamin and mineral brand; calcium supplements through its Caltrate brand, and vitamin C supplements through Emergen-C. The Brands under Respiratory consists of Otrivin, Theraflu, and Flonase. The Company's Pain Relief product includes Panadol, Voltaren and Advil brands. Its portfolio digestive health brands consists of Eno, Tums, and Fenistil.
HALEON PAKISTAN LIMITED 
